Topic: Adapt Pharma

U.S. Surgeon General Jerome Adams discussed the administration's strategy to combat the opioid epidemic, focusing on the widespread distribution of the overdose-reversal drug Naloxone (Narcan). Congress has approved $6 billion in funding, with $50 million specifically for Naloxone. Adams is working with pharmaceutical companies like Adapt Pharma to ensure that cost is not a barrier to access for insured and uninsured individuals.

The Los Angeles Sheriff's Department is equipping 3,000 deputies with Naloxone, branded as Narcan, to combat the opioid epidemic. Concerns are raised that the aggressive marketing and over-the-counter availability of nasal spray Narcan may inadvertently propagate heroin use by removing the fear of overdose. Adapt Pharma is identified as the manufacturer benefiting from the unrelenting media promotion of the product.

Adapt Pharma holds a virtual monopoly on the first FDA-approved nasal form of Naloxone, leading to speculation about a future IPO driven by heavy public relations. A shift in discussion critiques a Viceland documentary regarding the burka ban in France. The documentary is criticized for focusing on schoolgirls' clothing choices rather than addressing the cultural tensions in European "no-go zones."